You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
美因基因(06667.HK)上半年淨利潤同比增長5.3% 消費級基因檢測服務同比收入增長
格隆匯 08-30 22:21

格隆匯8月30日丨美因基因(06667.HK)公佈中期業績,2024年上半年,公司收益為人民幣1.07億元,同比增長8.5%;毛利為人民幣6961.8萬元,同比增長6.6%;淨利潤為人民幣3696.9萬元,同比增長5.3%,基本每股盈利人民幣0.18元。

截至2024年6月30日止六個月,實現總收入人民幣1.07億元,增幅為8.5%。其中消費級基因檢測服務及癌症篩查服務於截至2024年6月30日止六個月所產生的收入分別為人民幣1.04億元及人民幣290萬元。消費級基因檢測服務同比收入增長,主要由於公司以積極進取的態勢,不斷探索新的銷售場景與渠道。通過深入開展市場調研,充分挖掘潛在銷售機遇,拓展多元化銷售路徑,使產品銷售模式更具靈活性與多樣性。同時,在產品設計領域持續創新,不斷豐富產品矩陣,優化產品結構,推動收入穩步增長。

作為中國領先的基因檢測平台公司,我們專注於消費級基因檢測及癌症篩查服務。自2016年成立以來至2024年6月30日,公司累計進行了超過21百萬次基因檢測,其中截至2024年6月30日止六個月平均每月進行超過400,000次檢測。

截至2024年6月30日,公司與中國超過340個城市的近1,900家醫療保健機構合作,其中體檢中心約佔我們機構客户總數的52%,公司的銷售及營銷網絡使我們能夠向大部分中國人口提供基因檢測服務。此外,公司與多家電子商務及線上醫療保健平台合作,以擴大及完善銷售及營銷網絡。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account